BREXAFEMME® Pregnancy Safety Study

BREXAFEMME® (ibrexafungerp tablets) Pregnancy Safety Study

This is a pregnancy outcomes study in women exposed to BREXAFEMME® (ibrexafungerp tablets) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving last dose of the treatment. BREXAFEMME® is contraindicated during pregnancy because animal studies have indicated that it may cause fetal harm.

The purpose of this study is to monitor and document the pregnancy outcomes of women who have taken BREXAFEMME® during pregnancy. The study will observe patients throughout pregnancy and will monitor their infants from birth to the age of 12 months.

Have questions?

Call the toll-free number 1‑888‑982‑7299 and speak to a study representative.



Am I eligible?

You may participate in this study:

  1. If you have taken BREXAFEMME® while pregnant or,
  2. If conception is estimated to have occurred within 4 days after the last dose of BREXAFEMME®.
Click on the link to fill the form for participation.
Contact me (patient)

Information for pregnant women

Download the Information Booklet for pregnant women who may have taken BREXAFEMME® during pregnancy.

DOWNLOAD


Information for healthcare providers

Learn more about it by clicking the below link.

For Healthcare Provider

How do I participate?
Fill out the Contact me (patient) to have a study representative contact you with more information.


Call the toll-free number 1‑888‑982‑7299 and speak to a study representative.


Ask your healthcare provider to help you complete the
Contact me (HCP).

For the latest important safety information, please refer to the full Prescribing Information and Patient Information. This is not intended to replace discussions with your healthcare provider.